IOST unveils new token economics: 97% of newly issued tokens will go to the community
On 20 December, IOST announced in its official blog post that it has officially launched a strategic token evolution plan in order to establish itself as a Web3 payments infrastructure, which includes the following key components: an enhanced pledge mechanism, community priority distribution, multiple value protection measures, and a growth acceleration pool.
In addition, IOST released a new token economic model with the following highlights:
1. Token allocation is as follows: ① The supply of established IOST tokens will be strategically adjusted: existing circulating supply of approximately 21.32 billion tokens, with a new allocation for growth of 21.32 billion tokens. ② 97% of the newly issued tokens will be used for the community, which includes pledge rewards, eco-growth and merchant incentives; ③ 3% will be reserved for operating costs and team expansion.
2. The distribution of newly issued tokens is as follows: PayPIN node rewards (60%), airdrops and pledge airdrops (20%), PayFi community incentives (8%), community developer grants (5%), Nexus DAO (4%), and team (3%).
3. Token Destruction Mechanism: Four interrelated token destruction mechanisms have been implemented, including: transaction fee destruction, node MEV destruction, ecology-based destruction, and DAO governance mechanism destruction. The combination of the four destruction mechanisms is expected to result in significant deflation as network adoption grows, with total annual destruction projected to be approximately $8 million by the end of 2025.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly

XRP Ledger adds account control feature, enabling enterprises to manage assets offline.

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.